Mutations in the
unc-13 gene cause diverse defects in the nervous system. The mutants have uncoordinated movement, slow irregular pharyngeal pumping, and are resistant to an acetylcholinesterase (AchE) inhibitor, such as aldicarb. They also accumulate abnormally high levels of acetylcholine without altering the level of the precursor choline and choline acetyltransferase activity. It has also been found histochemically that the motor and sensory neurons are misplaced in the mutants. Furthermore, abnormal connections between major interneurons, AVA and AVD, through gap junctions as well as abnormal development of motor neurons have been found by reconstruction of part of the ventral nerve cord, using serial section electron microscopy. Molecular cloning of the
unc-13 gene and sequencing of the cDNA reveal that the product encodes a novel protein with a central domain, which has a sequence similar to that of the regulatory region, consisting of the CI and CII subdomains, of the protein kinase C (PKC). It has been demonstrated biochemically that UNC-13 is a high affinity receptor for phorbol esters and diacylglycerol, indistinguishable from PKC in terms of its affinity to the ligands and sensitivity to various PKC inhibitors. Mammalian homologues of
unc-13 have also been identified to be expressed exclusively in the brain. These results suggest that UNC-13 involves in a novel signal transduction pathway and plays crucial roles for the development and function of the nervous system. We have further analyzed a role of
unc-13 for neurotransmission by making double mutants between
unc-13 and other genes including
unc-18,
ace-2 and
ace-3. The
unc-18 gene plays a vital role in neurotransmitter release by interacting with syntaxin, consistent with the Unc-18 phenotype of the abnormally high level of acetylcholine accumulation. A double mutant between strong alleles of
unc-13 and
unc-18 has synthetic lethal phenotype, but a double mutant between their weak alleles is viable and shows a stronger locomotive defect than that of each of the single mutants. This phenotype of the double correlates with a higher level of acetylcholine accumulation than the additive levels of the accumulation in each of the single mutants. The
unc-13 ace-2 double mutant has better movement than the
unc-13 single mutant. Furthermore, analysis of doubles between
unc-13 and
ace-3 shows that higher sensitivity of
ace-3 against AchE inhibitors such as trichlorfon is suppressed by
unc-13 mutations. These results suggest that the
unc-13 signal transduction pathway may be parallel to or overlap with neurotransmitter release processes mediated by
unc-18. This putative role of UNC-13 is consistent with its molecular structure of the protein, which has three Ca2+ and phospholipid-binding domains similar to synaptotagmin. This hypothesis is further supported by the results that the UNC-13 protein is localized to neuronal processes in a punctate pattern, presumably to synaptic regions. This localization is not altered in neurons of the
unc-104 mutant, suggesting that UNC-13 locates on the plasma membrane side, not on the vesicle, in synaptic terminals. Molecular analysis of the
unc-13 transcript has revealed that the transcript is processed by alternative trans- and cis-splicing to produce at least three variants. This molecular diversity may explain the diverse defects in the
unc-13 nervous system.